Partnering at BeiGene

Partnering at
BeiGene

We are committed to partnering with academia, biotech and pharmaceutical companies around the world to jointly discover and develop innovative products that will bring meaningful treatments to cancer patients. BeiGene’s combination of a world-class clinical development team and an experienced commercial team in China differentiates us. Our business development team is dedicated to make a positive impact in the fight against cancers.

Signing

I have the privilege to lead the talented business development team here at BeiGene as we uncover new, promising cancer treatments. We are each focused on developing those innovative therapies thoughtfully so they can be made accessible to the patients who need them as quickly as possible.

Guillaume Vignon, Ph.D.
Guillaume Vignon, Senior Vice President, Business Development
  • 1700+

    Employees

  • 850+

    Scientists & Clinicians

  • 4

    Continents

Our Partners

Celgene Logo
Celgene

Read more about the global collaboration that formed in 2017.

Mirati Therapeutics Logo
Mirati Therapeutics

Read more about our exclusive license agreement for sitravatinib in the Asia Pacific Region.

Mei Pharma
MEI

Read more about this clinical collaboration agreement.

Zymeworks logo
Zymeworks

Read more about the license and collaboration agreements. 

Our Partnership with Celgene

China is an important market for Celgene, and our collaboration with BeiGene positions us exceptionally well to optimize research, manufacturing, and the long-term commercial potential of our portfolio in China.

Mark J. Alles, Chief Executive Officer of Celgene

This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.

Accept